- Neuland Laboratories has entered a development partnership with Canada-based LIR Life Sciences to support its transdermal GLP-1/GIP obesity program.
- The collaboration includes peptide development, testing, and manufacturing support for PK/PD studies and Phase I formulations.
Neuland Laboratories Limited has entered into a development partnership with LIR Life Sciences Corp to support the advancement of a transdermal GLP-1/GIP program for obesity treatment. The collaboration focuses on the development, testing, and manufacturing of cell-penetrating peptides (CPPs) for early-stage studies and Phase I formulations.
LIR Life Sciences, a biotechnology company based in Canada, is developing a patch-based transdermal delivery platform for GLP-1 therapies targeting obesity. According to the company, the non-invasive delivery system is intended to improve patient adherence and expand access compared with injectable formulations. The companies stated that there are currently no approved transdermal GLP-1 therapies on the market.
Under the agreement, Neuland will support pharmacokinetic and pharmacodynamic studies as part of the program’s early-stage development. The collaboration may expand into later-stage clinical and commercial contract manufacturing activities if development milestones are achieved.
The partnership also reflects Neuland’s expanding peptide CDMO capabilities. The company recently invested in peptide infrastructure, including a $20 million process development laboratory and a multi-phase commercial peptide manufacturing facility at its Bonthapally campus in Hyderabad. Module one of the facility, representing approximately $30 million in investment and 6,370 liters of capacity, is expected to become operational by mid-2026.
“LIR Life’s transdermal approach represents a novel application of GLP-1 therapies, and we look forward to supporting the development of their CPP platform through our integrated peptide capabilities.”
Saharsh Davuluri, CEO of Neuland Laboratories
